Alessandro Doria

Professor in the Department of Epidemiology

Department of Epidemiology

Joslin Diabetes Center One Joslin Place
Section on Genetics and Epidemiology, Joslin Diabetes Center Room 445A
Boston, MA 02215
Phone: 617.309.2406

Other Affiliations

Professor of Medicine, Harvard Medical School
Senior Investigator, Joslin Diabetes Center


Dr. Doria’s research is aimed at identifying predisposing factors for the long-term complications of diabetes and using this knowledge to find novel approaches to tackle these health problems. To this end, he has developed a research program that draws on the large diabetic population of the Joslin Clinic and applies the tools of epidemiology and genetics.

In the area of coronary artery disease (CAD) – one of the most important causes of morbidity and mortality in diabetes – he has made three major discoveries:

  1. He found that the 9p21 CAD locus – the strongest genetic factor contributing to CAD in the general population – plays an even larger role in Type 2 diabetes, due to a synergism with poor glycemic control (JAMA 2008). Since the 9p21 locus regulates the expression of cyclin-dependent kinase inhibitors, such interactive effect implicates alterations of the cell cycle in the atherogenic effects of hyperglycemia, suggesting this pathway as a novel target for preventive therapies.
  2. He has identified a novel CAD locus that influences cardiovascular risk only in the presence of diabetes (JAMA 2013). This is the only CAD gene specific to diabetic subjects that has been identified to date. The CAD-predisposing variant at this locus is associated with lower expression of the GLUL (glutamine synthase)gene and with a distinctive metabolic profile implicating glutamate metabolism and the gamma-glutamyl cycle as novel targets to sever the link between diabetes and atherosclerosis.
  3. He has discovered two genetic markers that influence the cardiovascular effects of intensive glycemic control and can be used to select diabetic patients who are most likely to derive benefit rather than harm from this intervention (Diabetes Care 2016). These findings illustrate how gene x environment interactions can be harnessed to maximize the cost-effectiveness of diabetes treatments through precision medicine algorithms.

In the area of diabetic kidney disease (DKD) – the other major cause of morbidity and mortality among diabetic patients – Dr. Doria has identified serum uric acid as a predictor of kidney function decline in Type 1 diabetes (Diabetes Care 2010). Based on this observation, he designed and led a major NIH-funded, multicenter clinical trial investigating whether the urate-lowering drug allopurinol can prevent early kidney function loss in type 1 diabetes (PERL study, NCT02017171). The largest RCT funded by the NIH in the DKD area, PERL had several transformative features such as: 1. the focus on Type 1 diabetic patients in the early stages of DKD, 2. the inclusion of diabetic subjects who are losing kidney function in the presence as well as in the absence of albuminuria, and 3. the use of measured rather than estimated glomerular filtration rate as the primary outcome. The trial, completed in 2019, did not find a clinically meaningful benefit of allopurinol on kidney function in diabetes, but established a network of high-quality investigators and clinical sites that can be leveraged for trials of other interventions aimed at preventing kidney function loss in diabetes. The PERL cohort is being followed over time through an observational study (PERLage).

In parallel with his research on diabetic complications, Dr. Doria has also been studying maturity onset diabetes of the young (MODY) – a form of familial diabetes. He has identified BLK (PNAS 2009) and APPL1 (AJHG 2015) as new MODY genes and previously unrecognized modulators of insulin synthesis and secretion.


M.D., 1985, University of Padua (Italy)
Ph.D., 1993, University of Modena (Italy)
M.P.H., 2006, Harvard School of Public Health